Patient/advocate, Diane Redington and Dr. Michael Birrer discuss the results of GCS Project research to-date and where the research is headed. This is part two of a nine part series. Dr. Birrer discusses the fact that doctors typically treat ovarian carcinosarcoma the same as ovarian cancer, but they are NOT … Continue reading Research (Part 2) with Dr. Michael Birrer [VIDEO]
Patient/advocate, Diane Redington and Dr. Michael Birrer discuss the results of GCS Project research to-date and where the research is headed. This is part one of a nine part series. Dr. Birrer states that they have already had initial results. They are doing what Dr. Birrer calls a “molecular deep … Continue reading Research (Part 1) with Dr. Michael Birrer [VIDEO]
An interview with Dr. Birrer, leading researcher, on emerging immunotherapies with Gynecologic Carcinosarcoma cancer (MMMT).
An interview with Dr. Birrer who is leading the current research on MMMT through the Gynecologic Carcinosarcoma (GCS) Project. Tissue samples are needed.
An interview with Dr. Birrer and Diane Redington about the initial results of research being done on Gynecologic Carcinosarcoma at Mass General Hospital.
This is my first personal post on our new website. I am overwhelmed by the response to the site and I hope that means we are on the right track. The site is a work in progress. I will share stories of some amazing women as we go forward. Thanks for … Continue reading The GCS Project Update – Sept 2016
During a round table discussion on One Live TV, Michael J. Birrer, MD, PhD, explains new research for ovarian cancer in non-platinum-based chemotherapies, particularly PARP inhibition. Published on Apr 22, 2015.
In this video from Mass General Hospital from May 2016, it was announced that Phase II funding had been received for a multi-institution project to study patients who have survived ovarian cancer for 10 or more years. Published on May 6, 2016.
In this video, Dr. Michael Birrer talks about targeting either VEGF or ANG2 in gynecologic cancers. VEGF stimulates tumor vessel growth, while ANG2 stabilizes the vessels. Published on Nov 25, 2015.
In this video from Onc Live TV, Dr. Birrer discusses how progression-free survival and overall survival are holding back the approval of drugs for ovarian cancer patients. Published on Oct 16, 2013.